Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$37.1 million.

  • Spyre Therapeutics' Free Cash Flow fell 2615.82% to -$37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$161.9 million, marking a year-over-year decrease of 702.56%. This contributed to the annual value of -$157.4 million for FY2024, which is 5755.18% down from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Free Cash Flow is -$37.1 million, which was down 2615.82% from -$46.6 million recorded in Q2 2025.
  • Spyre Therapeutics' Free Cash Flow's 5-year high stood at $2.1 million during Q2 2021, with a 5-year trough of -$62.2 million in Q2 2024.
  • In the last 5 years, Spyre Therapeutics' Free Cash Flow had a median value of -$26.3 million in 2022 and averaged -$27.1 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 10989.49% in 2021, then plummeted by 110745.61% in 2022.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Free Cash Flow stood at -$19.3 million in 2021, then grew by 5.85% to -$18.1 million in 2022, then crashed by 71.09% to -$31.0 million in 2023, then fell by 19.86% to -$37.2 million in 2024, then grew by 0.22% to -$37.1 million in 2025.
  • Its Free Cash Flow stands at -$37.1 million for Q3 2025, versus -$46.6 million for Q2 2025 and -$41.0 million for Q1 2025.